Tebentafusp
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Trial Timeline
Feb 14, 2025 → Feb 17, 2031
NCT ID
NCT06627244About Tebentafusp
Tebentafusp is a phase 2 stage product being developed by Immunocore for Metastatic Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06627244. Target conditions include Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04960891 | Pre-clinical | Active |
| NCT06070012 | Phase 2 | Recruiting |
| NCT06627244 | Phase 2 | Recruiting |
| NCT06246149 | Phase 3 | Recruiting |
| NCT05315258 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic Uveal Melanoma